Hyderabad-based pharma player Laurus Labs has received a licence from the Defence Research & Development Organisation (DRDO) for manufacturing and marketing Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India. The licence to Laurus Labs has been granted by DRDO as part of efforts to make the drug affordable and accessible to patients.
DRDO had recently invited expression of interest (EoI) from other pharma companies for manufacturing this drug and had said it would grant licences to 15 companies on a first-come, first-served basis. Meanwhile, the Council of Scientific & Industrial Research institution Indian Institute of Chemical Technology (CSIR-IICT) has been licencing the know-how for 2-DG synthesis to other companies, including Lee Pharma, Suven Pharma, Anthem Biosciences and Nosch Labs.
India has a very old and rich history, and many places have changed their names…
For the Andhra Pradesh capital city project the World Bank has released the $340 million…
A political turnaround happened as the Viktor Orban has been ousted from the power after…
Department of the Posts Karnataka Postal Circle has unveiled the commemorative postage stamps and the…
To strengthen the India's Maritime Security Framework the Indian Navy will host the first edition…
Perfume has always been an important part of human life. It is made by mixing…